Trials / Recruiting
RecruitingNCT05954312
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 290 (estimated)
- Sponsor
- Vividion Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VVD-130037 | Oral tablets |
| DRUG | Docetaxel | IV infusion |
| DRUG | Paclitaxel | IV infusion |
| DRUG | Pembrolizumab | IV infusion |
Timeline
- Start date
- 2023-07-28
- Primary completion
- 2030-08-31
- Completion
- 2031-02-28
- First posted
- 2023-07-20
- Last updated
- 2026-03-18
Locations
25 sites across 3 countries: United States, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05954312. Inclusion in this directory is not an endorsement.